Weight Loss

$98/month* 

The #1 prescribed branded oral weight-management medication in adults is now FDA-approved for weight management in children ages 12-17.

No injections.  A once-daily oral medication that requires no training to administer and can fit seamlessly into any patient’s lifestyle. 

  Proven results. Qsymia was studied in 2 large trials that involved 3,754 patients 18 years and older whose BMI was 27 kg/m2 or greater. For the subjects in the 2 studies the average baseline weight was 256 lbs and 227 lbs, and the average baseline waist circumference was 47 inches and 45 inches. Patients were randomized to placebo, phentermine 3.75 mg/topiramate 23 mg (starter dose), phentermine 7.5 mg/topiramate 46 mg (recommended dose), or phentermine 15 mg/topiramate 92 mg (top dose). In these trials, it was recommended that patients eat a wellbalanced diet and reduce their caloric intake by 500 kcal/day  

Varies (see below)

Ozempic is a once-weekly injectable. The starting dose of Ozempic is 0.25 mg injected once weekly for four weeks. Then, your dose is moved up to 0.5 mg once weekly. After that, your dose may be increased every four weeks up to 2mg once weekly, depending on how you respond to the medication.

Contraindicated in patients with personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Sublingual Semaglutide is a daily oral tablet that is placed under the tongue. By taking the Semaglutide once daily, there have been no reports of hunger cravings. 

Rybelsus is a daily oral tablet. 

Wegovy is a once-weekly injectable. 

Semaglutide / Cyanocobalamin

Sublingual Tablet (SLT). 

 Varies (see below)

 Tirzepatide is a once-weekly injectable.  The recommended starting dosage of Tirzepatide is 2.5 mg injected subcutaneously (SubQ) once weekly. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control. After 4 weeks, increase the dosage to 5 mg, once weekly. If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. The maximum dosage of Tirzepatide is 15 mg per week. Inject Tirzepatide SubQ in the abdomen, thigh, or upper arm, and rotate injection sites. Administer Tirzepatide once weekly, any time of day, with or without meals.  

Tirzepatide is a synthetic linear peptide molecule containing 39 amino acids. It is the first agent that functions as a dual agonist for the two main human GLP-1 and GIP incretins, and has impressive glycemic efficacy. Moreover, it is the first effective drug to have demonstrated notable body weight loss in a phase 3 study in patients with T2D. Tirzepatide has significantly better therapeutic efficacy than current drugs such as semaglutide and insulin degludec.